Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$264.90
▼ $0.77 (-0.3%)
Market data updated: 09/17 02:11 AM
Fundamentals updated: 09/16/2026
News analyzed: 09/17/2026
Market Cap
$42.89B
Day Range
$262.44 - $267.89
52-Week Range
$148.05 - $310.50
Beta
—
Next Earnings
18.11.2026
VEEV is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
-2.5% (1Y)
Strengths: 16/26 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🟢 Bullish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Earnings per share (EPS) growth
Earnings per share (EPS) growth: 25.9%
Growth
Biggest negative driver
Calmar Ratio (return vs. drawdown)
Calmar: 0.17 (3y annualized return 8.7% / max drawdown 50.5%)
Risk
Signal tension
Growth scores strong (71/100), but fair-value analysis scores this stock as relatively expensive (45/100) — the growth story and the current price aren't fully aligned.
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
as of 09/04/202668
This Week
70
7D Ago
→ -2
Stable
Technical
68
7D Ago: 84
↓ -16
Fundamental
76
7D Ago: 76
→ 0
Growth
71
7D Ago: 71
→ 0
Valuation
45
7D Ago: 45
→ 0
News
100
7D Ago: 80
↑ +20
Quality
58
7D Ago: 58
→ 0
Risk
48
7D Ago: 48
→ 0
Biggest Improvements
Biggest Declines
📊 Score History
68
Today
—
30D
—
90D
—
1Y
🕰️ Signal Timeline
What StockIQ actually saw for this stock, and what happened after each signal — real data, not a forecast.
8d ago · $275.09
Evidence: Euphoria score crossed 55 (now 55)
What happened after
🐂🐻 Investment Thesis
🐂 Bull Case
⚖️ Base Case
68 / 100
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🕰️ StockIQ Time Machine
What did StockIQ know — and when? Pick a date from the real accumulated history.
As of August 29, 2026
Then
73
$276.69
Now
68
$264.90
What happened since
Signals detected by this date
No signals detected by this date
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
71
Quality
58
Value
45
Momentum
68
Risk
48
Sentiment
100
Fundamental
76
Institutional
0
Stocks with a similar DNA right now
SCANNING VEEV...
Recent media coverage of Veeva Systems highlights its rapid expansion in AI-driven software solutions for the biopharma industry. Key themes include the global adoption of its AI-powered Vault CRM suite by major clients like Regeneron and Biogen, the launch of Veeva Falcon Safety, and the company’s raised fiscal 2027 outlook driven by strong Vault CRM migrations and AI-driven growth. Analysts note its increasing role as core infrastructure in healthcare workflows while acknowledging market saturation as a potential long-term concern.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Veeva Systems. News trend score: 100. Reason: 10 of the last 20 articles are positive, versus 1 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
41
🎯 Conviction (vs. Emotion)
41
Psychology
49
Fundamentals
76
Technical
68
Valuation
45
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
The price rise has far outpaced the actual improvement in fundamental data.
Price (3M)
+74%
Market Narrative
60
Fundamental Reality
41
Narrative Gap
+19
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
VEEV’s psychology is dominated by **euphoria**, as momentum, extreme overperformance, and positive sentiment align with irrational exuberance. The **narrative gap** (70 vs. 41) suggests traders are overestimating growth potential relative to fundamentals, while **overconfidence** (23) reflects detached pricing from earnings growth. **FOMO** (42) and **herding** (42) are secondary, with traders chasing gains and reacting to peer moves. The key question: *Will momentum sustain, or will the gap between narrative and reality trigger a reversion?*
Updated: 09/09/2026, 12:55 AM
What could change this?
👥 What the crowd believes
"Regeneron and Biogen have adopted its AI-powered Vault CRM suite globally"
"Vault CRM adoption, R&D growth and Falcon AI momentum support expanding revenue"
"Veeva raises its fiscal 2027 outlook as Vault CRM and AI momentum accelerate"
"Michael Burry Warns Red-Hot AI Stock Is Overvalued"
🧠 Market Brain events driving this
📈 11D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Walter Bagehot — 100/100
🔴 Weakest match
Morgan Housel — 14/100
🗣️ Why do they disagree?
The stark divide in verdicts for VEEV reflects deep methodological contrasts: value-focused investors like Benjamin Graham and his Enterprising Investor counterpart (scores 25 and 31) dismiss it outright, seeing no margin of safety or statistical cheapness, while contrarian liquidity experts like Walter Bagehot (score 100) see it as a resilient survivor of financial stress. Meanwhile, growth-oriented thinkers such as Philip Fisher (80) and Jesse Livermore (76) highlight its quality and positive momentum, contrasting sharply with cyclical skeptics like Howard Marks (32) and Samuel Nelson (24), who warn of late-cycle or overbought conditions. Even patient long-term thinkers like Morgan Housel (3) flag volatility as a behavioral risk, while efficient-market adherents (35) question whether active selection adds value over passive indexing. The debate hinges on whether VEEV’s strengths—liquidity, quality, or trend—outweigh its risks—valuation, cycle positioning, or speculative crowd dynamics.
Walter Bagehot
Lombard Street (1873)
🟢 100
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟢 80
Exceptional company quality by Fisher's standards
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟡 64
Mixed signal on whether growth translates to real profit
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟡 63
Mid-cycle — no strong signal either way
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟡 57
Reasonable but not a clear long-term holding
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 55
No clear trend — Livermore preferred to stay out of this
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🟡 52
Mixed — growth exists but the price already reflects much of it
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 51
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 46
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 38
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟡 36
Pattern consistent with a crowd delusion Mackay would flag
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🔴 32
Looks late-cycle — the position Marks would treat with extra caution
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🔴 31
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🔴 26
Risk/valuation combination Marks would flag as a caution sign
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🔴 25
Fails most of Graham's defensive criteria
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 14
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
⚠️ Partial data for this stock — score is less reliable — Data availability: 30%
Fact → Principle → Simulation
Based on the last 280 trading days, calculated from real price data. Click an indicator for details and a chart.
🟢 Most indicators support an uptrend (6 bullish · 3 bearish · 2 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear uptrend with no defined trading range in the period examined.
Low confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
75.5%
Operating Margin
28.7%
Net Margin
28.4%
EBITDA Margin
28.7%
ROE
12.6%
ROA
10.1%
ROIC
—
EPS
$5.55
Cash
$1.42B
Total Debt
—
Current Ratio
4.89
Debt/Equity
—
אין נתונים היסטוריים זמינים.
How is Fair Value calculated? →
Not enough cash-flow data to calculate a DCF model for this stock.
Book Value per Share
$43.20
Tangible Book Value per Share (Tangible NAV)
$40.39
Sentiment based on basic keywords (not AI) — 10 positive, 9 neutral, 1 negative out of the last 20 articles.
ChartMill · 16.9.2026
Yahoo · 15.9.2026
Yahoo · 15.9.2026
MT Newswires · 15.9.2026
Yahoo · 15.9.2026
PR Newswire · 15.9.2026
ChartMill · 14.9.2026
MarketBeat · 14.9.2026
Yahoo · 14.9.2026
MarketBeat · 14.9.2026
Yahoo · 14.9.2026
SeekingAlpha · 10.9.2026
SeekingAlpha · 9.9.2026
StockStory · 8.9.2026
Yahoo · 8.9.2026
MT Newswires · 8.9.2026
Yahoo · 7.9.2026
Barchart · 7.9.2026
SeekingAlpha · 4.9.2026
Yahoo · 4.9.2026
Veeva Systems (VEEV) currently has a StockIQ AI score of 68/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
VEEV currently scores 68/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
VEEV's technical score is 68/100, which currently reads as bullish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Earnings per share (EPS) growth: 25.9%; Net income growth: 27.3%; Operating margin is stable or improving over time.
Based on the real signals StockIQ computed: Calmar: 0.17 (3y annualized return 8.7% / max drawdown 50.5%); MACD histogram is negative — falling momentum; P/E: 49.1.
StockIQ has no recorded dividend payment history for VEEV.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 3 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Hung Priscilla | Open Market Sale | 9.9.2026 | 750 | -750 | $261.04 |
| Cabral Timothy S | Exercise of Derivative Securities | 1.9.2026 | 477 | -477 | — |
| Cabral Timothy S | Exercise of Derivative Securities | 1.9.2026 | 477 | +477 | — |
| Ritter Gordon | Other Transaction | 1.9.2026 | 15,585 | +15,585 | — |
| Wallach Matthew J | Exercise of Derivative Securities | 1.9.2026 | 460 | +460 | — |
| Hedley Mary Lynne | Exercise of Derivative Securities | 1.9.2026 | 477 | +477 | — |
| SEKHRI PAUL J | Exercise of Derivative Securities | 1.9.2026 | 460 | +460 | — |
| Carges Mark T | Exercise of Derivative Securities | 1.9.2026 | 493 | -493 | — |
| Ritter Gordon | Exercise of Derivative Securities | 1.9.2026 | 541 | -541 | — |
| Hung Priscilla | Exercise of Derivative Securities | 1.9.2026 | 477 | -477 | — |
| MOHR MARSHALL | Exercise of Derivative Securities | 1.9.2026 | 525 | +525 | — |
| Wallach Matthew J | Exercise of Derivative Securities | 1.9.2026 | 460 | -460 | — |
| Hedley Mary Lynne | Exercise of Derivative Securities | 1.9.2026 | 477 | -477 | — |
| MOHR MARSHALL | Exercise of Derivative Securities | 1.9.2026 | 525 | -525 | — |
| SEKHRI PAUL J | Exercise of Derivative Securities | 1.9.2026 | 460 | -460 | — |
| Ritter Gordon | Exercise of Derivative Securities | 1.9.2026 | 541 | +541 | — |
| Ritter Gordon | Other Transaction | 1.9.2026 | 250,000 | -250,000 | — |
| Hung Priscilla | Exercise of Derivative Securities | 1.9.2026 | 477 | +477 | — |
| Carges Mark T | Exercise of Derivative Securities | 1.9.2026 | 493 | +493 | — |
| Schwenger Thomas D. | Exercise of Derivative Securities | 27.8.2026 | 25,000 | -10,000 | — |
| Schwenger Thomas D. | Exercise of Derivative Securities | 27.8.2026 | 29,449 | +10,000 | $154.00 |
| Schwenger Thomas D. | Open Market Sale | 27.8.2026 | 19,449 | -10,000 | $281.33 |
| Schwenger Thomas D. | Open Market Sale | 27.8.2026 | 10,000 | -10,000 | $281.33 |
| Schwenger Thomas D. | Exercise of Derivative Securities | 27.8.2026 | 10,000 | -10,000 | — |
| Schwenger Thomas D. | Exercise of Derivative Securities | 27.8.2026 | 10,000 | +10,000 | $154.00 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
4,824,012 shares short as of 2026-08-31 · vs. 7,300,157 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
63.9% of trading volume this week was short selling, vs. 61.9% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology